Document is current
Any future updates will be listed below
-
Authors
Van Dam, S.
Krijgsman, D.
Küçükköse, E. https://orcid.org/0000-0002-8983-9464
Verdonschot, M. E. L.
Amini, M. https://orcid.org/0009-0009-8301-0178
Blokx, W. A. M.
Van Eijs, M. J. M. https://orcid.org/0000-0002-9763-6704
Verheijden, R. J. https://orcid.org/0000-0003-1966-1063
Kranenburg, O. https://orcid.org/0000-0002-2112-4390
Suijkerbuijk, K. P. M. https://orcid.org/0000-0003-3604-5430
Leusen, J. H. W.
Vercoulen, Y. https://orcid.org/0000-0002-5060-2603
-
Funding
Funding for this research was provided by:
Health Holland,
Oncode Institute
Health Holland, Top Sector Life Sciences and Health, reference number TKI-2017
- License Information
-
More Information
Article History
Received: 31 May 2024
Revised: 26 May 2025
Accepted: 21 July 2025
First Online: 2 September 2025
Competing interests
: Yvonne Vercoulen declares funding from AlfaSigma and TigaTx BV. Jeanette Leusen is the scientific founder and a shareholder of TigaTx BV, and was supported by Oncode Accelerator, a Dutch National Growth Fund project under grant number NGFOP2201. Karijn Suijkerbuijk has consulting/advisory relationships with: AbbVie and Sairopa. In addition, Karin Suijkerbuijk declares Research funding from TigaTx, Bristol Myers Squibb, Philips, Genmab, and Pierre Fabre which were all paid to institution.
